675 articles in this topic
Deleting CPT1a in mouse livers dramatically lowers ApoB-containing lipoproteins by accelerating clearance, revealing a new lipid metabolism target.
Elevated oxidized phospholipids independently predict major cardiac events after ACS, and alirocumab abolishes that risk signal.
A pooled analysis of 2,884 patients finds obicetrapib significantly reduces coronary events after 6 months, with striking lipid improvements.
In 2,040 coronary angiography patients, OxPL-apoB predicted MI-free survival but showed no link to platelet reactivity, implicating Lp(a) as the key mediator.
A pill-form GLP-1 receptor agonist significantly reduced multiple cardiovascular risk markers in both T2D and obesity patients over 26–36 weeks.
A proteomics screen of 2,920 plasma proteins identifies a 17-protein score that lifts heart failure prediction accuracy to 0.833 C-index in type 2 diabetes patients.
Leading cardiologists from Brigham and Johns Hopkins debate which imaging tool better directs primary prevention decisions.
Dr. Terry Simpson brings personal experience with FH, tirzepatide, and statins to a blunt takedown of health misinformation.
New molecular analysis reveals cardiac sarcoidosis triggers self-targeting antibodies against a desmosome protein, explaining its overlap with arrhythmic heart disease.
A large genome-first study reveals critical gaps in familial hypercholesterolemia diagnosis for people of African ancestry due to variant classification bias.
Johns Hopkins research finds combining cannabis edibles with alcohol impairs driving far beyond either substance alone, evading standard sobriety tests.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
